Highlights Newsletter 3
This newsletter presents you the following key sessions:
1. Video-interview with Laurie Sehn, MD, PhD, about the results of the phase II trial assessing the efficacy and safety
of the addition of polatuzumab to bendamustine and rituximab in patients with r/r DLBCL
2. Ixazomib, lenalidomide and dexamethasone for relapsed and refractory multiple myeloma – data from the Czech
Registry of Monoclonal Gammopathies
3. Ravulizumab shows noninferiority versus eculizumab in adult patients with paroxysmal nocturnal haemoglobinuria
naive to complement inhibitors
4. Ibrutinib lead-in followed by venetoclax in patients with chronic lymphocytic leukemia: phase II CAPTIVATE early
safety and efficacy results
5. DESTINY trial: sustained recurrence free survival in the second stopping year